The global next generation drug conjugates market is projected to grow from $3.9 billion in 2026 to $10.9 billion by 2033 at 15.3% CAGR, while the radionuclide drug conjugate segment is forecast to reach $20.22 billion by 2032 at 9.6% CAGR.
International Rare Disease Day on February 28 underscores challenges in diagnosing and treating rare genetic conditions, with patients facing years-long diagnostic delays and geographic barriers to accessing gene therapies.
Novartis has agreed to acquire Avidity Biosciences in the first half of 2026, obtaining its RNA therapeutics platform and neuromuscular disease pipeline. Avidity's cardiovascular RNA programs will be separated into a new independent company called Atrium.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07591779 |
Physical Activity Level at Home in CMT1A Patients: Wearable Sensor Assessment |
NOT_YET_RECRUITING | |
| NCT07287189 |
Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients |
RECRUITING | PHASE2 |
| NCT07250737 |
Managed Access Program for Del-zota in Participants With DMD Mutations Amenable to Exon 44 Skipping |
AVAILABLE | |
| NCT07171385 |
Posterior Chain EMG Patterns in Athletes With and Without Hamstring Injury |
COMPLETED | |
| NCT07136844 |
Gait Analysis Parameter and Upper Limb Evaluation in Adult Patients With Neurological or Metabolic Pathology |
RECRUITING | NA |
| NCT06827587 |
Efficacy and Safety of Efgartigimod Sequential Therapy with Telitacicept in Generalized Myasthenia Gravis |
NOT_YET_RECRUITING | NA |
| NCT06775561 |
Precision Diagnosis and Therapy for Rare Diseases by Interpreting Non-coding Genomes |
RECRUITING | |
| NCT06672237 |
A Phase 3 Study of NTLA-2001 in ATTRv-PN |
RECRUITING | PHASE3 |
| NCT06566651 |
Emotion Processing Among Patients With ALS |
RECRUITING | |
| NCT06553976 |
Spastic Paraplegia - Centers of Excellence Research Network |
RECRUITING |
